Clearly, the results are not evolutionary but revolutionary.

Clearly, the results reported in this issue of the journal are revolutionary.

The results are simply stunning.

The P-III is an evolutionary advance, not a revolutionary one.

These changes are happening at an evolutionary pace, not a revolutionary pace, but we want to manage for the long term.

Our care of patients with HER2-positive breast cancer must change today,